What the papers say – weekly digest (24/05/24)
Your weekly digest of the top healthcare stories, covering news published from 20/05/2024 – 24/05/2024. The Daily Telegraph Artificial intelligence that is twice as fast as doctors at… read more.
Your weekly digest of the top healthcare stories, covering news published from 20/05/2024 – 24/05/2024. The Daily Telegraph Artificial intelligence that is twice as fast as doctors at… read more.
Giving high-risk patients access to an obesity specialist through their regular primary care clinic increased their chances of receiving at least one evidence-based weight-management treatment, and led to… read more.
Amgen announced that the FDA has approved Imdelltra (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after… read more.
Patients who are treated with metformin for type 2 diabetes are less likely to develop a myeloproliferative neoplasm (MPN). Myeloproliferative neoplasms are cancers that occur when the body… read more.
Researchers will delve into emerging research in diabetes, obesity, reproductive health and other aspects of hormone health during the Endocrine Society’s ENDO 2024 news conferences June 1-4. The… read more.
Patients with very advanced solid tumors saw no significant improvement in overall survival after receiving systemic therapy, according to a study published today in JAMA Oncology by researchers at The University… read more.
A quarter of parents report that caffeine is basically part of their teen’s daily life, according to a national poll. Two in three parents think they know whether… read more.
Bristol Myers Squibb announced new four-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. After four… read more.
The latest findings from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, published today in The Lancet, provide new insights into health challenges and the risk… read more.
Shionogi & Co., Ltd. announced that its pivotal, double-blind, randomized, placebo-controlled global Phase III study (SCORPIO-HR) did not meet its primary endpoint of a statistically significant reduction in… read more.
The rate of colorectal cancer screenings more than doubled when patients were given a choice between which type of screening they wanted—a take-home kit or colonoscopy—compared to those… read more.
Prices paid to hospitals during 2022 by employers and private insurers for both inpatient and outpatient services averaged 254% of what Medicare would have paid, with wide variation… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.